EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Trastuzumab Duocarmazine in Pretreated Her2-Positive Breast Cancer: Has the “TULIP” Bloomed a Bit Too Late?

Akhil Santhosh

Indian Journal of Medical and Paediatric Oncology · 01.08.2025 · 46 (04) · 420-421

DOI: 10.1055/s-0045-1808100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Medical and Paediatric Oncology, erschienen am 01.08.2025. Verfasst von Akhil Santhosh. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We read the TULIP trial by Turner et al[ 1 ] that tested the role of trastuzumab duocarmazine (T-Duo) in recurrent HER2+ metastatic breast cancer. T-Duo (SYD 985) is a novel next-generation HER2-targeted antibody-drug conjugate (ADC) with a cleavable payload (vc-seco-DUBA) conjugated with trastuzumab. In this phase 3 open-label, randomized controlled trial, patients aged ≥ 18 years were randomized (in 2:1 ratio) to receive T-Duo or physician's choice (PC) therapy (lapatinib–capecitabine, capecitabine–trastuzumab, trastuzumab–vinorelbine, or trastuzumab–eribulin). Patients received a median of three prior lines of anti-HER2 therapies; of which 60.8 and 57.5% patients received pertuzumab and 2.1 and 1.4% patients received trastuzumab deruxtecan (T-DXd) in the experimental and control arms, respectively. The study met its primary endpoint of progression-free survival (PFS) prolongation in the T-Duo arm with a median PFS of 7 months (95% confidence interval [CI], 5.4–7.2) versus 4.9 months (95% CI, 4.0N5.5) for PC therapy. The overall response rate by central imaging review was 27.8% in the T-Duo arm versus 29.5% in the PC arm. The median duration of response was 15.1 months (95% CI, 5.7–15.1) for T-Duo versus 4.6 months (95% CI, 2.8–7.1) for PC. Overall survival results are currently immature. Ocular adverse events were notable with T-Duo (78.1% any grade, 21.2% grade 3). The incidence of interstitial lung disease and pneumonitis were similar to that seen with other anti-HER 2 ADCs like ado-trastuzumab emtansine (TDM1) and T-DXd. It is imperative that we understand that by the time this trial accrued, tremendous progress was already made in HER2-positive metastatic breast cancer space. Initially tested in third line and beyond in the DESTINY 02 trial[ 2 ] with impressive results, T-DXd went on to trump TDM1 in the subsequent DESTINY 03 study[ 3 ] and is currently the favored drug in the second-line therapy. Impressive central nervous system (CNS) response rates of 73.3 and 46.2% were received from the TUXEDO-1[ 4 ] and DEBBRAH[ 5 ] trials, respectively. Therefore, the activity of T-DXd supersedes any other anti-HER2 therapy. Hardly 2% of patients in TULIP received T-DXd and responses post-T-DXd with T-Duo are not known. The brain is a notable sanctuary site for recurrent HER2+ disease and up to 50% of patients develop brain metastases.[ 6 ] TULIP does not give us any idea regarding the intracranial efficacy of T-Duo. The hazard ratio for patients with brain metastases is not impressive, albeit this could be explained by the small patient population. Every patient with advanced cancer needs to live longer and live better. With 78% of ocular adverse events (20% grade 3 or more), T-Duo unfortunately cuts a sorry figure and hampers the coveted parameter of “quality of life.” Despite the use of prophylactic eye drops and regular ophthalmological examinations (slit lamp exam, corneal sensitivity testing, fluorescence tear film break-up time, and pachymetry), these adverse events could not be prevented. Also, they persisted for months and were slow to recover, unlike the case with some ADCs like tisotumab vedotin, where strict prophylaxis and timely dose modifications helped.[ 7 ] Duocarmazine payloads have an inherent risk of cardiotoxicity. In the dose-expansion study of T-Duo, reversible left ventricular dysfunction was reported in 11 patients (7% grade 1–2, 1% grade 3).[ 8 ] Readers are deprived of the same data in TULIP. The performance of an ADC depends upon four factors, namely, the stability of the linker molecule in plasma, activity and toxicity profile of the cytotoxic moiety, drug-to-antibody ratio (DAR), and membrane permeability. For T-Duo, the poor DAR (2.8:1) is compensated by the presence of a cleavable linker and a bystander effect, unlike TDM1. Nevertheless, all is not gloomy for this late entrant. The median PFS of 7 months in TULIP augurs well with the TH3RESA[ 9 ] and HER2CLIMB[ 10 ] data with TDM1 and tucatinib, respectively. Tucatinib scores above these two drugs in its ability to elicit good CNS control. T-DXd is almost being front-lined into the management of HER2-positive metastatic breast cancer and the DESTINY BREAST 09 results will be released soon. Hence, there is a huge scope of potential for new drugs as second and subsequent options in the therapeutic armamentarium of HER2-positive breast cancer. The low incidence of myelosuppression and nausea/vomiting with T-Duo makes it an ideal option to combine with other drugs. TDM1 is already being revived in this manner through the HER2CLIMB02[ 11 ] and CompassHER2RD trials, where it is combined with tucatinib in the metastatic and post-neoadjuvant-residual disease settings, respectively. ADC resistance may arise from defective internalization and trafficking pathways. Small molecules like tucatinib and neratinib are known to stabilize HER2 on the cell membrane facilitating the action of ADCs. Also, studies are underway combining T-Duo with poly(ADP-ribose) polymerase (PARP) inhibitors in locally advanced or metastatic solid tumors expressing HER2.[ 12 ] The rationale behind this strategy is the synthetic lethality offered by the alkylator payload and PARP inhibitors. Another possible avenue is the combination of immune checkpoint inhibitors with ADCs. ADCs are known to enhance antigen presentation through antibody-dependent cellular toxicity and increase the CD8+ flux into the tumor microenvironment. This was evident from the arm 6 of the BEGONIA trial where durvalumab + T-DXd elicited an overall response rate of 66.7%.[ 13 ] Lastly, an area where T-Duo can work wonders like T-DXd is the HER2-low subset of breast cancer. In the phase 1 study, 9/32 (28%) patients with HER2-low/HR+ and 6/15 (40%) patients with HER2-low/HR− patients had confirmed RECIST (Response Evaluation Criteria in Solid Tumors) responses.[ 6 ] T-Duo is also being tested in other HER2-positive metastatic solid tumors. Response rates as high as 25 and 39% were seen in urothelial and endometrial cancer, respectively.[ 8 ] Before writing off this drug, taking time to understand its mechanism of action and unique toxicity profile can help us better fit T-Duo into the ever-expanding therapeutic realm of targeted agents in HER2-positive breast cancer. With the arrival of T-DXd in the Indian markets and the latest cut in import taxes for novel life-saving anticancer drugs, it will be very difficult for T-Duo to find its place as a later line option in the management of HER2-positive metastatic breast cancer. Patient's Consent Patient consent is not required. Publication History Article published online: 30 April 2025 © 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

Zitieren

APA

Santhosh, A. (2025). Trastuzumab Duocarmazine in Pretreated Her2-Positive Breast Cancer: Has the “TULIP” Bloomed a Bit Too Late?. Indian Journal of Medical and Paediatric Oncology, 46(04), 420-421. https://doi.org/10.1055/s-0045-1808100

Vancouver

Santhosh A. Trastuzumab Duocarmazine in Pretreated Her2-Positive Breast Cancer: Has the “TULIP” Bloomed a Bit Too Late?. Indian Journal of Medical and Paediatric Oncology. 2025;46(04):420-421. doi:10.1055/s-0045-1808100

BibTeX
@article{Santhosh2025,
  author = {Santhosh, Akhil},
  title = {Trastuzumab Duocarmazine in Pretreated Her2-Positive Breast Cancer: Has the “TULIP” Bloomed a Bit Too Late?},
  journal = {Indian Journal of Medical and Paediatric Oncology},
  year = {2025},
  volume = {46},
  number = {04},
  pages = {420--421},
  doi = {10.1055/s-0045-1808100}
}
Kostenlos starten →